Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Right Of Use Asset Obtained Reduced In Exchange For Operating Lease Liability From Lease Modifications

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept iova:RightOfUseAssetObtainedReducedInExchangeForOperatingLeaseLiabilityFromLeaseModifications.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s right of use asset obtained reduced in exchange for operating lease liability from lease modifications?
Iovance Biotherapeutics, Inc. (IOVA) reported right of use asset obtained reduced in exchange for operating lease liability from lease modifications of $359K in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s right of use asset obtained reduced in exchange for operating lease liability from lease modifications changed year-over-year?
Iovance Biotherapeutics, Inc.'s right of use asset obtained reduced in exchange for operating lease liability from lease modifications increased by 125.1% year-over-year, from -$1.43M to $359K.